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Overcoming intratumoural heterogeneity
for reproducible molecular risk
stratification: a case study in advanced
kidney cancer
Alexander L. R. Lubbock1,7, Grant D. Stewart1,2,8, Fiach C. O’Mahony1,2, Alexander Laird1,2, Peter Mullen3,
Marie O’Donnell2,4, Thomas Powles5, David J. Harrison2,3 and Ian M. Overton1,6*
Abstract
Background: Metastatic clear cell renal cell cancer (mccRCC) portends a poor prognosis and urgently requires better
clinical tools for prognostication as well as for prediction of response to treatment. Considerable investment in
molecular risk stratification has sought to overcome the performance ceiling encountered by methods restricted to
traditional clinical parameters. However, replication of results has proven challenging, and intratumoural heterogeneity
(ITH) may confound attempts at tissue-based stratification.
Methods: We investigated the influence of confounding ITH on the performance of a novel molecular prognostic
model, enabled by pathologist-guided multiregion sampling (n = 183) of geographically separated mccRCC cohorts
from the SuMR trial (development, n = 22) and the SCOTRRCC study (validation, n = 22). Tumour protein levels
quantified by reverse phase protein array (RPPA) were investigated alongside clinical variables. Regularised wrapper
selection identified features for Cox multivariate analysis with overall survival as the primary endpoint.
Results: The optimal subset of variables in the final stratification model consisted of N-cadherin, EPCAM, Age, mTOR
(NEAT). Risk groups from NEAT had a markedly different prognosis in the validation cohort (log-rank p = 7.62 × 10−7;
hazard ratio (HR) 37.9, 95% confidence interval 4.1–353.8) and 2-year survival rates (accuracy = 82%, Matthews
correlation coefficient = 0.62). Comparisons with established clinico-pathological scores suggest favourable
performance for NEAT (Net reclassification improvement 7.1% vs International Metastatic Database Consortium score,
25.4% vs Memorial Sloan Kettering Cancer Center score). Limitations include the relatively small cohorts and associated
wide confidence intervals on predictive performance. Our multiregion sampling approach enabled investigation of
NEAT validation when limiting the number of samples analysed per tumour, which significantly degraded performance.
Indeed, sample selection could change risk group assignment for 64% of patients, and prognostication with one
sample per patient performed only slightly better than random expectation (median logHR = 0.109). Low grade tissue
was associated with 3.5-fold greater variation in predicted risk than high grade (p = 0.044).
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Conclusions: This case study in mccRCC quantitatively demonstrates the critical importance of tumour sampling for
the success of molecular biomarker studies research where ITH is a factor. The NEAT model shows promise for mccRCC
prognostication and warrants follow-up in larger cohorts. Our work evidences actionable parameters to guide sample
collection (tumour coverage, size, grade) to inform the development of reproducible molecular risk stratification methods.
Keywords: Cancer, Tumour heterogeneity, Prognostic markers, Renal cell carcinoma, Tumour biomarkers
Background
There is a great unmet need for better treatment and
diagnosis of kidney cancer, which remains the most le-
thal of all genitourinary malignancies. Five-year survival
in renal cell cancer (RCC) is approximately 40% overall,
10% in metastatic disease [1, 2]. Clear cell RCC (ccRCC)
represents about 80% of cases, and around one-third of
patients present with metastasis. Current risk stratifica-
tion of advanced ccRCC uses clinico-pathological scor-
ing systems, for example, the International Metastatic
Database Consortium (IMDC) [3] and Memorial Sloan
Kettering Cancer Center (MSKCC) [4] scores. Molecular
markers promise to overcome the performance plateau
encountered by clinico-pathological variables; however,
success rates have historically been low [5–8].
Sunitinib is a first-line treatment for metastatic ccRCC
(mccRCC), doubling median progression-free survival
compared with older immunotherapies such as IL-2 and
interferon-α [9, 10]. Sunitinib targets tumour, endothe-
lial cells and pericytes, where the mechanism of action
includes competitive inhibition of multiple receptor
tyrosine kinases (RTKs) [11, 12]. Up to 70% of patients
treated with sunitinib show little or no tumour response
[10], although they may derive a survival benefit, despite
incurring significant toxicity. Improved algorithms are
critically needed to guide treatment decisions for current
and emerging modalities [6, 7, 13].
Advances in prediction of treatment response and
prognostication may be severely hindered by intratumoural
heterogeneity (ITH) [14–16]. Indeed, percutaneous biopsy
of mccRCC is a poor guide for pathological assessment of
prognostic features [17]. Development of tumour sampling
approaches to capture ITH is key for discovery and valid-
ation of candidate molecular risk stratification algorithms
[6, 7, 13, 15]. We studied protein expression ITH in the
context of mccRCC risk stratification, controlling for clin-
ical variables, and developed a novel prognostic model
(NEAT, for N-cadherin, EPCAM, Age, mTOR) that com-
pares well with established clinico-pathological scores. The
variables selected in NEAT inform mccRCC biology and
suggest sunitinib action directly on tumour growth signal-
ling. We quantitatively show a dramatic effect of tumour
sampling on NEAT performance in a validation cohort
receiving current standard treatment and demonstrate
parameters pertinent to the development of molecular
diagnostic tools for cancer medicine. We present rec-
ommendations that guide tumour sample selection for
biomarker research in order to overcome variability in
the presence of ITH. Indeed, sampling protocols may
determine the success or failure of attempts to validate
molecular biomarkers where ITH is a factor.
Methods
Cohorts and tissue samples
This study examined two geographically separated cohorts
of mccRCC patients with multiregion tumour sampling
(Table 1). Excluding necrotic tissue, 108 and 75 fresh-
frozen samples respectively were analysed from develop-
ment and validation cohorts. The development cohort was
drawn from the SuMR phase II clinical trial of upfront
sunitinib (NCT01024205, n = 22, London [18]). The val-
idation cohort were cytoreductive nephrectomy patients
from the SCOTRRCC study and received standard of care
treatment (validation, n = 22, Scotland [1, 19]). The devel-
opment cohort received three cycles of sunitinib 50 mg
(4 weeks on, 2 weeks off) prior to nephrectomy; following
nephrectomy, the validation cohort received either su-
nitinib (n = 8), similar targeted agents (n = 3) or no drug
(n = 11). These cohorts were enriched for patients with
a poor or intermediate prognosis, in line with the SuMR
trial selection criteria [18]. Median follow-up time, defined
as time of entry to death or last contact, was 22.0,
12.3 months respectively for the development, validation
cohorts. Univariate Cox regression for mTOR and overall
survival analysed an overlapping cohort (n = 45) which in-
cluded an additional patient [20]. Comparisons of cohort
characteristics used Mann–Whitney, Fisher or binomial
tests as appropriate; p values were two-tailed and cor-
rected for multiple hypothesis testing [21]. Net reclassi-
fication improvement (NRI) confidence intervals were
calculated using bootstrapping [22, 23].
Multiregion tumour sampling
Details of multiregion tissue mapping and sample prep-
aration are given in [24]. Briefly, samples taken forward
for reverse phase protein array (RPPA) analysis were
spatially separated and selected to represent morpho-
logical diversity across the tumour. Fresh-frozen tumours
were divided into spatially mapped 1 cm3 pieces; cryostat
sections of each piece were examined to confirm ccRCC
Lubbock et al. BMC Medicine  (2017) 15:118 Page 2 of 12
Table 1 Clinical characteristics of cohorts studied
Cohort Total Development (SuMR) Validation (SCOTRRCC)
Number of patients 44 22 22
Age, median (range)a 66.5 (38.2–79.3) 64.5 (44–78) 67.5 (38.2–79.3)
Overall survival (months):b
Median 16.2 23.5 12.3
Interquartile range 9.1–25.9 14.8–29.8 7.6–18.8
Number censored 22 10 12
Modes (bimodal model) 10.6, 27.3 10.2, 27.4 11.6, 27.5
Number of samples per tumoura median (range) 4 (1–10) 4 (1–10) 4 (2–8)
Male genderb 29 15 14
Fuhrman grade:b
4 9 1 8
3 22 12 10
2 13 9 4
Stage:b
T4 4 4 0
T3 33 13 20
T2 6 4 2
T1 1 1 0
Performance status:c
KPS >80 (unavailable) 34 (1) 13 (0) 21 (1)
Anaemiab,+ (unavailable) 22 (2) 12 (0) 10 (2)
Raised calciumb (unavailable) 8 (7) 5 (0) 3 (7)
Raised LDHc (unavailable) 10 (15) 5 (0) 5 (15)
Neutrophil count >70% upper limit of normalb (unavailable) 9 (2) 2 (0) 7 (2)
Platelet count >400b (unavailable) 12 (2) 6 (0) 6 (2)
VHL mutationb 31 14 17
Renal response at surgery:
Partial response – 2 –
Stable disease – 20 –
Number of metastatic sites:b
1 19 6 13
2 18 11 7
3 7 5 2
IMDC class:b
Intermediate 26 12 14
Poor 16 10 6
Unavailable 2 0 2
MSKCC class:b
Favourable/intermediate: 26 13 13
Poor 12 9 3
Unavailable 6 0 6
+Hb <130 (M), <110 (F); ap < 0.05; bp > 0.05; cp < 10-4
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status and for morphological classification. Up to four
samples per morphologically distinct region in each
tumour were selected for protein extraction; each of these
samples reflected circa 50–75 mm3 of tissue.
Intratumoural protein expression variance in sunitinib-
exposed and sunitinib-naïve cancers
Fifty-five protein targets were investigated by RPPA, se-
lected according to prior knowledge and validated anti-
body availability [20]. Each tumour sample analysed by
RPPA reflected 50–75 mg of lysed tissue taken from a
1 cm3 spatially mapped region [24]. Protein extraction,
RPPA slide spotting, immunofluorescence data acquisition,
data processing and identification of four markers that had
increased variance associated with sunitinib treatment
(p < 0.05) were described previously [20, 25]. Briefly,
1 mg/ml lysates were spotted onto nitrocellulose slides
using a robotic spotter, and immunofluorescence imaging
was performed with an Odyssey scanner (Li-Cor Biosci-
ences, Lincoln, NB, USA). Image processing and logistic
curve fitting to the RPPA dilution series employed Micro-
Vigene software (VigeneTech, Carlisle, MA, USA). Protein
variance per tumour was estimated using batch-corrected,
normalised RPPA expression values from multiregion
sampling, comparing the ratio of mean-squared errors be-
tween sunitinib-exposed and sunitinib-naïve cohorts per
protein marker in an analysis of variance (ANOVA)
framework. Statistical significance of variance differences
was assessed using the F test only when relevant assump-
tions held, assessed by the Lillefors and Fligner-Kileen
tests [20]. Ranking by the protein expression variance
log-ratio between sunitinib-exposed and sunitinib-naïve
tumours identified a further two proteins of potential
interest where variance was greater than at least one of
the four significant markers; these proteins did not meet
F-test assumptions and so were not assessed in our previ-
ous work using the ANOVA framework. Therefore, six
proteins (CA9, N-cadherin (CDH2), EPCAM, mTOR
(MTOR), MLH1, BCL2) were candidate molecular vari-
ables input into feature selection (described in the fol-
lowing section). The antibodies used for these candidate
variables are listed in (supplementary) Table S1 of
Additional file 1.
Selection of variables and multivariate modelling
Variables were selected for Cox proportional hazards re-
gression to overall survival on the development cohort
using wrapper feature selection with backward elimin-
ation regularised by Bayesian information criterion (BIC)
[26, 27]. Backward elimination iteratively removed a sin-
gle feature (i.e. protein expression or a clinical param-
eter) at each step, selecting for the greatest improvement
in BIC value. BIC regularisation seeks to balance the
model complexity (number of parameters, including
candidate features) against the model likelihood (fit to
the data); therefore, this approach removes features with
the smallest contribution to model likelihood while
penalising redundancy. The selection procedure termi-
nated with a final model when removing any single fea-
ture did not improve BIC. The 'coxph' and 'stepAIC'
functions were used respectively from the 'survival' and
'MASS' R libraries (with model complexity penalty speci-
fied for BIC) [28].
Comparison with established clinico-pathological scores
IMDC and MSKCC scores were calculated according to
the relevant clinical parameters [3, 4]. Sufficient data were
available to calculate the IMDC score for 20/22 patients in
the validation cohort, all of whom fell into the 'intermedi-
ate' or 'poor' categories. MSKCC score was used to group
patients into (1) favourable/intermediate and (2) poor
prognosis; sufficient data were available to classify 14/22
patients. A further two patients were on the borderline of
intermediate or poor prognosis with MSKCC parameters
due to missing data, but had short survival times and were
assigned to the poor prognosis group. Therefore, two am-
biguous values were resolved in favour of the MSKCC
score performance, making comparison with NEAT more
stringent; hence 16/22 patients were assigned MSKCC
scores. All patients in the development cohort had suffi-
cient data for IMDC and MSKCC scoring. The reported
hazard ratio (HR) for NEAT reflects stratification into
either better or worse than average risk groups (i.e.
classification threshold of logHR = 0); this threshold
was predetermined and not derived from exploratory
data analysis. HR reported for IMDC, MSKCC follows
the groupings described above.
Investigating stratification performance with reduced
number of samples per tumour
In order to evaluate tumour sampling effects on NEAT
performance, a subsampling procedure produced datasets
taking a maximum number of tumour samples (MNTS)
of 1, 2 or 3 per tumour (and thus per patient). This ap-
proach employed Sobol sampling [29]; see supplemen-
tary methods in Additional file 1 for further details.
The selected tumour samples were used to calculate
median protein expression per patient as input for the
NEAT algorithm. Patient age was unchanged. The HR
and log-rank p value for stratification into 'high' and
'low' risk groups defined by NEAT logHR = 0 were cal-
culated. This analysis was performed on 106 datasets
per MNTS examined, where each dataset represented a
unique combination of samples across all patients in
the validation cohort. Therefore, every patient was rep-
resented in each of the 106 datasets; thus, 106 NEAT
HR and log-rank p values were generated for each
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MNTS, representing predictive performance distribu-
tions across the different tumour sample combinations.
Results
Cohort characteristics
The two mccRCC cohorts were similar across many
characteristics (Table 1), although statistically significant
differences were identified for Karnofsky performance
status, elevated lactate dehydrogenase and age. Cluster-
ing analysis of overall survival (OS) using regularised
Gaussian mixture modelling for unsupervised cardinality
selection identified two modes (clusters) in the com-
bined cohorts (n = 44, Fig. 1). The longer survival cluster
had a median OS (mOS) of 27.3 months, matching the
favourable or intermediate prognosis subgroups defined
in pivotal studies. For example, the favourable subgroup
reported for the MSKCC score had mOS of 30 months
[4], mOS for the IMDC score intermediate subgroup was
27 months [3] and a further independent study reported
mOS of 26 months for the favourable subgroup [30]. The
shorter survival cluster had mOS of 10.6 months, which is
similar to reported mOS values across poor and inter-
mediate prognosis subgroups in the preceding studies
[3, 4, 30]. Greater representation of the shorter survival
cluster in the validation cohort was partly due to cen-
soring and also arose from the drug response selection
criterion for the development cohort [18]. However,
survival times for the validation and development co-
horts were not significantly different. Therefore, the
population studied (n = 44) has a bimodal OS distribu-
tion that aligns with that of subgroups identified in lar-
ger mccRCC cohorts [3, 4, 30].
The NEAT algorithm for risk stratification of patients with
metastatic renal cancer
A machine learning approach using regularised wrapper
selection [27] with Cox multivariate analysis [26] on the
development cohort identified a novel model for mccRCC
patient risk stratification by overall survival. We hypothe-
sised that proteins with increased intratumoural variance
following therapy may function as markers of resistance
or aggressiveness and so enable prognostication. Indeed,
factors underlying changes in tumour composition with
treatment include clonal selection and proteomic diversity
across isogenic cell populations [16, 31, 32]. Twelve vari-
ables were examined, including six key clinical parameters
(grade, gender, age, neutrophils, haemoglobin, IMDC
score [3]) and values for six proteins where intratumoural
variance was greater in sunitinib-exposed mccRCC. Prog-
nostic variables automatically identified by machine learn-
ing were N-cadherin, EPCAM, Age and mTOR (NEAT),
controlling for the above clinical parameters. Protein ex-
pression values for these markers in the development and
validation cohorts are shown in Fig. 2. The resulting
multivariate Cox proportional hazards model for the de-
velopment cohort had likelihood ratio test p = 1.18 × 10−4,
and all selected variables were individually significant in
the multivariate model (Table 2).
The interesting positive relationship of mTOR with
survival was followed up in an overlapping cohort and
was significant in univariate Cox regression (p = 0.034).
The proportional hazards assumption was not invali-
dated (Grambsch-Therneau test [33], (supplementary)
Table S2 of Additional file 1). The HR was calculated
from relative protein expression values and age in years
at diagnosis as follows:
Hazard ratio = exp(8.927 N-cadherin + 3.800 EPCAM+
0.129 Age - 18.385 mTOR)
NEAT performed well on the geographically separated
validation and development cohorts (Fig. 3). This work
reflects evidence level IB [34], where development used
prospective clinical trial data and validation was per-
formed with patients who received current standard ther-
apy. Concordance index (C index) [35] values for the
NEAT, IMDC and MSKCC score risk groups in the valid-
ation cohort were respectively 0.77 (95% CI 0.66–0.88),
0.76 (95% CI 0.60–0.92) and 0.64 (95% CI 0.54–0.75). Net
reclassification improvement [22] values for NEAT on the
validation cohort were 7.1% vs IMDC (95% CI −24.8%,
Fig. 1 Overall survival distributions for the development (SuMR) and
validation (SCOTRRCC) cohorts. Kernel density plots are shown for all
survival data, including censored data. The above distributions indicate
bimodality for both cohorts studied, with similar mode positions around
11 and 27 months. These survival modes align with survival subgroups
reported in pivotal studies [3, 4, 30]. The development cohort (blue) had
the greatest proportion of patients in the mode centred around
27 months, reaching a density value of 0.037. The majority of
patients in the validation cohort (red) are in the survival mode
around 11 months (reaching a density value of 0.049), partly due
to greater censoring in this cohort
Lubbock et al. BMC Medicine  (2017) 15:118 Page 5 of 12
39.0%) and 25.4% vs MSKCC score (95% CI −25.7%,
76.5%), shown in Table 3.
Tumour sampling is a critical limiting factor for validation
of molecular stratification approaches
The overall approach to investigate the effects of tumour
sampling on predictive performance is summarised in
Fig. 4. Three distributions of NEAT hazard ratio and
log-rank p value were generated to reflect sampling 1, 2
or 3 regions per tumour in the validation cohort; these
distributions capture NEAT performance for different
sample combinations taken across tumours and patients.
For example, consider three patients, each with RPPA
data from four different tumour samples. If a single sam-
ple is taken from each patient for NEAT analysis, there
would be 43 (i.e. 64) unique combinations of tumour
samples across the three patients. Validation power rose
significantly at each increase in the number of tumour
samples taken per patient, and the full dataset with a
median of four spatially separated samples per tumour
appeared adequate, conferring good predictive power.
NEAT overall performance on the validation cohort was
poor when limited to a single tumour sample per pa-
tient, and was significantly impaired with two samples
per patient (Fig. 5a). In the single sample regime, stratifi-
cation into good and poor prognosis groups was only
just better than random expectation (median logHR =
0.109, binomial p < 10−322); strong statistical significance
is due to the large datasets studied. Taking two samples
per tumour gave improved stratification performance
over a single sample (median logHR= 1.614, Mann–Whitney
p < 10−324), and substantial further improvement was found
when taking three samples (median logHR = 3.030,
Mann–Whitney p < 10−324). Application of NEAT to
different subsets of tumour samples per individual pa-
tient changed risk group assignment for 64% of the val-
idation cohort (Fig. 5b). Interestingly, the median
variance in per-patient HR was 3.5-fold greater in low
grade samples than high grade samples (Mann–Whitney
p = 0.044). In order to further investigate the independent
prognostic power of individual tumour regions, we com-
pared prediction using expression values averaged across
all available samples for each individual against the best
possible results obtained using only one sample per
tumour. Validation using all of the available samples per
tumour outperformed even the most predictive single
sample taken (p < 10−6).
Discussion
This study examines the effect of sampling on the per-
formance of a novel molecular prognostic approach,
NEAT, using protein measurements from 183 regions
across 44 mccRCC tumours. The unique development
cohort from the SuMR trial allowed for selection of pro-
teins that had increased intratumoural expression vari-
ance with treatment; we hypothesised that these proteins
may be markers of aggressiveness and therefore useful in
prognostication. Although the cohorts are relatively small,
NEAT gave statistically robust stratification of the inde-
pendent validation cohort by overall survival (Fig. 3a). The
trend for favourable NEAT performance relative to the
IMDC, MSKCC scores would benefit from investigation
in a larger cohort, and the good performance of IMDC
relative to the MSKCC score aligns with previous work
[3]. To our knowledge, the mccRCC cohorts analysed here
are the largest available with RPPA data from pathologist-
guided, multiregion tumour sampling. Our approach to
capture grade diversity is likely to better represent ITH
than standard sampling methods. Furthermore, each
sample analysed by RPPA reflects a large tissue volume
(circa 50–75 mm3) relative to standard approaches
based on tissue sections from formalin-fixed paraffin
embedded material such as tissue microarray analysis
Fig. 2 Expression values for NEAT molecular features. Protein
concentration values determined by RPPA for validation (yellow) and
development (blue) cohorts are shown for all samples (log2), including
multiple datapoints per tumour. Therefore, a single tumour may
contribute datapoints across the full range of expression values shown
in each box plot. Relative expression values increase from the bottom
(−9) to the top (−5.2) of the y-axis. The distributions are overlapping,
with a shift towards higher expression in the development cohort
Table 2 Multivariate Cox proportional hazards model for overall
survival, fitted on the development cohort
Feature HR (95% confidence interval) p
mTOR 1.04 × 10–8 (6.09 × 10–4 – 1.71 × 10–13) 0.001
EPCAM 44.7 (845.6–2.36) 0.011
N-Cadherin 7.53 × 103 (2.76 × 106 – 20.71) 0.003
Age 1.14 (1.27–1.02) 0.018
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(<0.2 mm3 per region). Therefore, the RPPA data ana-
lysed cover a higher proportion of the overall tumour vol-
ume relative to standard approaches. The sampling
approaches may be an important enabling factor in NEAT
reproducibility and hence good validation performance,
despite the relatively small cohorts studied. The RPPA
technique offers potential as a quantitative alternative to
IHC and has already been applied in a clinical setting
through the Clinical Laboratory Improvement Amend-
ments (CLIA) facility certification process [36, 37]. The
NEAT model might ultimately be applied to inform deci-
sion making and patient management in several areas: (1)
monitoring and follow-up, (2) recruitment into clinical tri-
als with new agents, (3) treatment decisions, for example,
for patients on the borderline of receiving drug due to
other factors and (4) patient counselling.
The NEAT development and validation cohorts were
relatively small (n = 44 total), which is associated with
increased risk of type II error and wide confidence inter-
vals on predictive performance. Cytoreductive nephrec-
tomy is standard clinical practice, and the use of upfront
tyrosine kinase inhibitor (TKI) treatment is variable,
limiting recruitment of a uniform cohort (as was ob-
tained from the SuMR clinical trial) for NEAT develop-
ment. A further limiting factor on the size of cohorts in
our study was the availability of appropriately consented
fresh-frozen material with multiregion sampling and
pathology assessment for RPPA analysis. Our approach to
discover resistance biomarkers required multiregion sam-
pling of tumour tissue from patients treated with upfront
sunitinib in order to enable comparison of candidate
marker variance in sunitinib-exposed and sunitinib-naïve
material. Therefore, the cohorts received different treat-
ment regimens and also had significant differences in
some clinical characteristics. NEAT performed well on
both cohorts despite these differences, and so might be
broadly useful for prognostication of mccRCC. Further
study of NEAT performance on an independent upfront
sunitinib cohort would be of interest to further explore
potential clinical utility, such as to inform decision making
about performing a cytoreductive nephrectomy [38].
Subsampling of the multiregion RPPA data showed
that validation of the NEAT prognostic model was critic-
ally dependent on the number of samples analysed per
Fig. 3 Kaplan-Meier curves for overall survival risk stratification by N-Cadherin, EPCAM, Age and mTOR (NEAT). a Validation cohort. The high risk
(n = 4, dashed line) and low risk (n = 18, dotted line) groups identified by NEAT have markedly different prognoses (log-rank p = 7.62 × 10−7) with
respective 2-year survival rates of 0% and 78% (precision = 100%, recall = 50%, specificity = 100%, accuracy = 82%, Matthews correlation coefficient =
0.62). Data analysed were independent of wrapper feature selection and of fitting model coefficients. b Development cohort. The identified features
and model coefficients were learned on the data shown, which therefore does not provide an independent test. High risk (n = 14, dashed line) and low
risk (n = 8, dotted line) groups are clearly separated (log-rank p = 0.00553), with respective 2-year survival rates of 43% and 100%. (precision = 57%,
recall = 100%, specificity = 57%, accuracy = 73%, Matthews correlation coefficient = 0.57)
Table 3 Performance characteristics of NEAT and clinico-pathological scores
Cohort Percentage NRI (95% CI) HR (95% CI)
NEAT vs IMDC NEAT vs MSKCC+ NEAT IMDC MSKCC
Validation 7.1a (–24.8, 39.0) 25.4b (–25.7, 76.5) 37.89 (4.1, 353.8) 7.317a (1.54, 34.69) 14.39b (1.24, 165.7)
Development 25.0 (–34.8, 84.8) 23.3 (–28.3, 74.9) 10.649 (1.35, 84.08) 1.378 (0.44, 4.36) 3.577 (1.00, 12.85)
NRI net reclassification improvement, HR Hazard ratio, NEAT N-cadherin EPCAM Age mTOR multivariate model, IMDC International Metastatic Database
Consortium, MSKCC Memorial Sloan Kettering Cancer Center
Values reflect assignment of either high risk or low risk status (methods)
an = 20 due to data availability
bn = 16 due to data availability
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tumour. Indeed, the model's performance in risk stratifi-
cation improved significantly at each increase in the
number of tumour regions analysed (Fig. 5a). These re-
sults therefore evidence the benefit of more extensive
tumour sampling both for biomarker development and
also in validation studies where the sampling protocol
may contribute to a reported lack of reproducibility. The
efficacy of even the most promising tissue-based bio-
markers is diminished by ITH [39], and identification of
molecular predictors that are unaffected by ITH may be
very challenging. Indeed, cancer biomarkers have histor-
ically suffered from a high attrition rate [8]. The avail-
able data provided for subsampling analysis of one, two
and three samples per tumour; however, analysis with
the full dataset (median of four samples) performed best.
In principle, even higher sampling rates may be benefi-
cial; several patients where >3 samples were taken,
reflecting larger tumours, show considerable variation in
HR even when large numbers of samples are analysed
(Fig. 5b). One patient where eight tumour regions were
examined had substantial variation in NEAT HR even
across subsets containing six samples. Therefore, the in-
fluence of tumour sampling on predicted risk is clear for
individual patients. These results also evidence benefit of
sampling in proportion to tumour volume for molecular
diagnostics. We found considerably greater variance in
HR for low grade over high grade samples; thus, tumour
biomarker studies would benefit from performing more
extensive sampling of low grade regions. This result also
underlines the additional information provided by
NEAT. Indeed, the automatic feature selection process
deprioritised grade relative to molecular variables. Prog-
nostication using all of the multiple tumour samples gave
better risk stratification than provided by analysis of any
single sample in isolation. Therefore, NEAT analysis with
multiple tumour regions captures information unavailable
in any single sample; this information may reflect the
adaptive potential arising from ITH [40] and also might
include aspects of disease progression such as the degree
of vascularisation or the length of time since initial dis-
semination competence.
With regard to the individual components of the NEAT
model, the positive association of mTOR with overall
survival was the strongest, most significant feature and
was also found in univariate analysis of an overlapping
cohort. The mTOR pathway is an important mediator
of RTK growth signalling [41]. Improved prognosis as-
sociated with elevated mTOR in NEAT suggests that
tumours dependent upon mTOR have enhanced sensi-
tivity to sunitinib. Therefore, sunitinib may act directly
on tumour cells to inhibit mccRCC growth, consistent
with results in ovarian cancer that VEGF stimulates the
mTOR pathway [42]. Additionally, the mTORC1 com-
plex, which includes mTOR, exerts negative feedback
on RTKs to suppress proliferation and survival [41];
this negative feedback could enhance therapeutic RTK
inhibition by sunitinib. Notably, mTOR inhibitors are
currently in clinical use (for example, everolimus), pos-
sibly in conjunction with sunitinib or similar agents.
Our results suggest caution in co-treating with mTOR
inhibitors and sunitinib, resonating with the poor per-
formance of everolimus followed by sunitinib in the
Fig. 4 Overall approach for investigation of the effect of subsampling on NEAT predictive performance. A total of 106 combinations of n = {1,2,3}
samples per tumour were analysed across the 22 patients in the validation cohort where multiregion sampling encompassed identified morphological
intratumoural heterogeneity (top left). A median of four samples was taken per tumour. The distributions of logHR and log-rank p values across the 106
samples taken for each value of n (bottom right) are given at readable size in Fig. 5
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RECORD-3 trial [43]. Consistent with previous results,
for example [44, 45], a significant negative association
with survival was identified for N-cadherin, a canon-
ical marker of epithelial to mesenchymal transition. Add-
itionally, N-cadherin is expressed by endothelial cells and
so may also represent a surrogate for vascularisation [46].
Age is a known RCC prognostic factor that was not se-
lected for the IMDC score [3, 47, 48]. Our analysis took
age as continuous values, which may partly explain selec-
tion of this variable for the NEAT model and not in the
IMDC analysis, which dichotomised age at 60 years [49].
The IMDC score was not selected by our machine learning
approach which implies that, in the development cohort,
prognostic information captured by the IMDC score over-
laps with that provided by the NEAT variables. High
EPCAM expression is also associated with poor prognosis
in NEAT and multiple cancers [50, 51], although reports
link EPCAM with better prognosis in localised RCC; see,
for example, [52, 53]. The contrasting association with sur-
vival for EPCAM in NEAT may be due to differences be-
tween advanced and localised ccRCC, technologies used
and context-specific function, for example, in signal trans-
duction by nuclear localisation of the cleaved intracellular
domain [54].
Fig. 5 Stratification of the validation cohort critically depends upon tumour sampling. a Values of NEAT logHR (top) and p values (log-rank test,
bottom) are shown for subsampled datasets generated by taking a maximum of one (dashed line), two (dotted line) or three (dot-dash line)
samples per tumour. The vertical line in each graph indicates NEAT performance using all available samples. Stratification performance improves
significantly as the number of samples taken increases. b Variation in per-patient NEAT HR driven by tumour sampling. Each plot corresponds to
a patient and shows the distribution of logHR from NEAT across the available tumour samples. Vertical bars indicate logHR range for every possible
combination of the specified number of samples. Therefore, logHR calculated using all samples is shown on the right of each plot as a single point. For
many patients (14/22, 64%) the logHR distribution encompasses the classification threshold (logHR = 0); hence risk group assignment is critically
influenced by the tumour sample(s) analysed
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Conclusions
Multiregion sampling to capture mccRCC grade diver-
sity enabled investigation of ITH impact on risk stratifi-
cation with a novel protein-based prognostic model,
NEAT (N-Cadherin, EPCAM, Age, mTOR). NEAT com-
pares well with established clinico-pathological scores on
a geographically separate independent validation cohort
who received current standard therapy. Results show
that evaluation or attempted use of any molecular prog-
nostic and predictive methods with few tumour samples
will lead to variable performance and low reproducibil-
ity. We demonstrate parameters (tumour coverage, size,
grade) that may be used to inform sampling in order to
enhance biomarker reproducibility, and results underline
the critical importance of addressing heterogeneity to
realise the promise of molecular stratification approaches.
Through studies such as TRACERx [55], we anticipate
that extensive multiregion sampling will become standard
procedure for discovery and validation of molecular diag-
nostics across a range of cancer types.
Recommendations arising from our research include
the following: (1) biomarker validation studies should
implement tumour sampling protocols that match as
closely as possible to the discovery work; (2) clinical bio-
marker research and ultimately front-line diagnostic ap-
proaches may benefit from greater tumour sampling
rates; (3) clinical parameters (including tumour grade,
size, coverage) can guide sample selection, and investiga-
tion of additional parameters to inform sampling may be
useful; (4) optimisation of tumour sampling rate and
sample selection protocols are important research areas
to enable advances in stratified cancer medicine.
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